Alaunos Therapeutics, Inc. (TCRT) Financial Ratios
24 years of historical data (2001–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
2.07
↓-36% vs avg
5yr avg: 3.22
30Y Low1.5·High15.2
ROE
↓
-111.8%
-10% vs avg
5yr avg: -101.2%
30Y Low-265%·High-44%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
TCRT Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Alaunos Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $6M | $3M | $17M | $141M | $234M | $528M | $793M | $268M | $567M | $698M | $1.0B |
| Enterprise Value | $5M | $2M | $11M | $122M | $188M | $418M | $715M | $207M | $496M | $617M | $901M |
| P/E Ratio → | -0.91 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 582.19 | 305.84 | 3394.19 | 48.24 | 587.17 | — | — | 1838.09 | 88.73 | 101.68 | 240.58 |
| P/B Ratio | 2.07 | 1.48 | 2.69 | 3.66 | 4.03 | 4.26 | 8.34 | 3.14 | — | — | 11.93 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
TCRT EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 196.74 | 2181.79 | 41.74 | 471.70 | — | — | 1415.29 | 77.63 | 89.86 | 208.10 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
TCRT Profitability
Margins and return-on-capital ratios measuring operating efficiency
Alaunos Therapeutics, Inc. earns an operating margin of -48120.0%. Operating margins have compressed from -1201.4% to -48120.0% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -111.8% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | -95960.0% | 100.0% | 100.0% | — | — | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Margin | -48120.0% | -48120.0% | -685340.0% | -1201.4% | -19484.7% | — | — | -36921.9% | -837.3% | -2409.4% | -2772.4% |
| Net Profit Margin | -46790.0% | -46790.0% | -702800.0% | -1291.2% | -19786.7% | — | — | -36381.5% | -850.3% | -2409.2% | -2772.1% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -111.8% | -111.8% | -156.7% | -78.1% | -86.5% | -73.0% | -130.5% | -62.1% | — | -3282.0% | -198.1% |
| ROA | -84.9% | -84.9% | -96.0% | -47.2% | -65.3% | -62.6% | -115.4% | -52.9% | -51.3% | -127.1% | -120.7% |
| ROIC | -593.1% | -593.1% | -259.5% | -166.3% | -450.4% | -384.5% | -209.3% | — | — | — | — |
| ROCE | -115.0% | -115.0% | -145.6% | -58.7% | -75.0% | -71.6% | -63.5% | -63.3% | -61.0% | -146.2% | -141.3% |
TCRT Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $1M exceeds total debt of $0, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | 0.52 | 0.52 | 0.04 | 0.02 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.53 | -0.96 | -0.49 | -0.79 | -0.89 | -0.81 | -0.72 | — | — | -1.61 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -17.84 | -11.13 | -65.22 | — | — | — | -64.45 | — | — |
Net cash position: cash ($1M) exceeds total debt ($0)
TCRT Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Alaunos Therapeutics, Inc.'s current ratio of 3.98x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 2.23x to 3.98x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.98 | 3.98 | 4.22 | 2.23 | 4.91 | 7.11 | 8.42 | 8.89 | 4.35 | 6.63 | 8.42 |
| Quick Ratio | 3.98 | 3.98 | 4.22 | 1.65 | 4.91 | 7.11 | 8.42 | 8.89 | 4.35 | 6.63 | 8.42 |
| Cash Ratio | 1.58 | 1.58 | 3.10 | 1.62 | 4.74 | 6.26 | 6.37 | 6.51 | 3.40 | 5.13 | 7.76 |
| Asset Turnover | — | 0.00 | 0.00 | 0.04 | 0.00 | — | — | 0.00 | 0.06 | 0.06 | 0.03 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 182.50 | 73.00 | 0.50 | 1018.88 | — | — | 4660.00 | 1.09 | 1.12 | 37.58 |
TCRT Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Alaunos Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | 6.3% | — | 1.0% | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.6% | 0.4% | 0.2% | 0.1% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 6.9% | 0.4% | 1.2% | 0.1% |
| Shares Outstanding | — | $2M | $2M | $1M | $1M | $1M | $1M | $956724 | $912921 | $869276 | $836107 |
Peer Comparison
Compare TCRT with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 TCRTYou | $6M | -0.9 | — | — | 100.0% | -48120.0% | -111.8% | -593.1% | — |
 IOVA | $1B | -3.3 | — | — | 97.2% | -153.1% | -55.5% | -48.9% | — |
 FATE | $280M | -2.1 | — | — | — | -2222.4% | -51.8% | -36.5% | — |
 TCRX | $157M | -1.2 | — | — | 72.2% | -1315.4% | -71.3% | -90.7% | — |
 IMVT | $6B | -10.0 | — | — | — | — | -62.5% | — | — |
 KYMR | $7B | -22.9 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 CRIS | $76M | -1.0 | — | — | 99.5% | -348.4% | -138.8% | — | — |
 NKTR | $2B | -8.6 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 TGTX | $7B | 15.5 | 57.1 | — | 83.6% | 20.0% | 102.8% | 16.4% | 2.1 |
 ILMN | $21B | 25.5 | 19.6 | 22.6 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
 TMO | $176B | 26.8 | 19.0 | 28.0 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
| Healthcare Median | — | 22.3 | 14.5 | 18.5 | 64.0% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 24 years · Updated daily
See TCRT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TCRT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TCRT vs IOVA
Side-by-side business, growth, and profitability comparison vs Iovance Biotherapeutics, Inc..
Start ComparisonTCRT — Frequently Asked Questions
Quick answers to the most common questions about buying TCRT stock.
What is Alaunos Therapeutics, Inc.'s P/E ratio?
Alaunos Therapeutics, Inc.'s current P/E ratio is -0.9x. This places it at the 50th percentile of its historical range.
What is Alaunos Therapeutics, Inc.'s ROE?
Alaunos Therapeutics, Inc.'s return on equity (ROE) is -111.8%. The historical average is -118.4%.
Is TCRT stock overvalued?
Based on historical data, Alaunos Therapeutics, Inc. is trading at a P/E of -0.9x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Alaunos Therapeutics, Inc.'s profit margins?
Alaunos Therapeutics, Inc. has 100.0% gross margin and -48120.0% operating margin.